Radiation therapy firm Nomos has received Food and Drug Administration 510(k) clearance for Peregrine, a Monte Carlo-based dose calculation system. Peregrine, which was exclusively licensed from Lawrence Livermore National Laboratory in July 1999, allows doctors and clinicians to know precisely the amount of dose being delivered to both the tumor and surrounding sensitive tissue, according to Nomos.
The Sewickley, PA-based firm will initially deploy Peregrine with its Corvus intensity-modulated radiation therapy (IMRT) system. A stand-alone version of Peregrine will subsequently be developed to work with other treatment planning systems, according to Nomos.
The company says Peregrine is the first commercial Monte Carlo-based dose calculation system to be introduced to the U.S. radiation therapy market, and also the first to include specific accuracy claims in its FDA submission.
By AuntMinnie.com staff writersOctober 9, 2000
Copyright © 2000 AuntMinnie.com
